https://www.selleckchem.com/pr....oducts/pf-07220060.h
city, caution is advised whenever CDK4/6i is given concurrently with RT. Management paradigms now allow for systemic targeted drugs before central nervous system (CNS)-directed radiation therapy (RT) in selected asymptomatic patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). We aimed to quantify how novel targeted agents with improved CNS activity, such as second-generation anaplastic lymphoma kinase (ALK) inhibitors (eg, alectinib), might affect the role of CNS-directed RT. This retrospective, observational
Like
Comment
Share
